Management of Pulmonary Hypertension Associated with Chronic Lung Disease

 

 Buy Article Permissions and Reprints

Abstract

Pulmonary hypertension (PH) is a common complication of chronic lung diseases, particularly in chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILD) and especially in advanced disease. It is associated with greater mortality and worse clinical course. Given the high prevalence of some respiratory disorders and because lung parenchymal abnormalities might be present in other PH groups, the appropriate diagnosis of PH associated with respiratory disease represents a clinical challenge. Patients with chronic lung disease presenting symptoms that exceed those expected by the pulmonary disease should be further evaluated by echocardiography. Confirmatory right heart catheterization is indicated in candidates to surgical treatments, suspected severe PH potentially amenable with targeted therapy, and, in general, in those conditions where the result of the hemodynamic assessment will determine treatment options. The treatment of choice for these patients who are hypoxemic is long-term oxygen therapy and pulmonary rehabilitation to improve symptoms. Lung transplant is the only curative therapy and can be considered in appropriate cases. Conventional vasodilators or drugs approved for pulmonary arterial hypertension (PAH) are not recommended in patients with mild-to-moderate PH because they may impair gas exchange and their lack of efficacy shown in randomized controlled trials. Patients with severe PH (as defined by pulmonary vascular resistance >5 Wood units) should be referred to a center with expertise in PH and lung diseases and ideally included in randomized controlled trials. Targeted PAH therapy might be considered in this subset of patients, with careful monitoring of gas exchange. In patients with ILD, inhaled treprostinil has been shown to improve functional ability and to delay clinical worsening.

Publication History

Article published online:
24 July 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Humbert M, Kovacs G, Hoeper MM. et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61 (01) 2200879
  CrossrefPubMedGoogle Scholar
• 2 Gall H, Felix JF, Schneck FK. et al. The Giessen pulmonary hypertension registry: survival in pulmonary hypertension subgroups. J Hear Lung Transplant 2017; 36 (09) 957-967
  CrossrefPubMedGoogle Scholar
• 3 Hurdman J, Condliffe R, Elliot CA. et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41 (06) 1292-1301
  CrossrefPubMedGoogle Scholar
• 4 Nathan SD, Barbera JA, Gaine SP. et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53 (01) 1801914
  CrossrefPubMedGoogle Scholar
• 5 Galiè N, Humbert M, Vachiery JL. et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37 (01) 67-119
  CrossrefPubMedGoogle Scholar
• 6 Olsson KM, Hoeper MM, Pausch C. et al. Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. Eur Respir J 2021; 58 (02) 2101483
  CrossrefPubMedGoogle Scholar
• 7 Zeder K, Avian A, Bachmaier G. et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J 2021; 58 (02) 2100944
  CrossrefPubMedGoogle Scholar
• 8 Chaouat A, Bugnet AS, Kadaoui N. et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172 (02) 189-194
  CrossrefPubMedGoogle Scholar
• 9 Andersen KH, Iversen M, Kjaergaard J. et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012; 31 (04) 373-380
  CrossrefPubMedGoogle Scholar
• 10 Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30 (04) 715-721
  CrossrefPubMedGoogle Scholar
• 11 Dobarro D, Schreiber BE, Handler C, Beynon H, Denton CP, Coghlan JG. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol 2013; 111 (02) 278-285
  CrossrefPubMedGoogle Scholar
• 12 Adir Y, Humbert M, Chaouat A. Sleep-related breathing disorders and pulmonary hypertension. Eur Respir J 2021; 57 (01) 2002258
  CrossrefPubMedGoogle Scholar
• 13 Hoeper MM, Pausch C, Grünig E. et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Hear lung Transplant 2020; 39 (12) 1435-1444
  CrossrefPubMedGoogle Scholar
• 14 Lewis RA, Thompson AAR, Billings CG. et al. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J 2020; 55 (06) 2000041
  CrossrefPubMedGoogle Scholar
• 15 Hoeper MM, Dwivedi K, Pausch C. et al. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir Med 2022; 10 (10) 937-948
  CrossrefPubMedGoogle Scholar
• 16 Peinado VI, Pizarro S, Barberà JA. Pulmonary vascular involvement in COPD. Chest 2008; 134 (04) 808-814
  CrossrefPubMedGoogle Scholar
• 17 Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21 (05) 892-905
  CrossrefPubMedGoogle Scholar
• 18 Peinado VI, Barberà JA, Ramirez J. et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998; 274 (06) L908-L913
  PubMedGoogle Scholar
• 19 Kovacs G, Agusti A, Barberà JA. et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease. is there a pulmonary vascular phenotype?. Am J Respir Crit Care Med 2018; 198 (08) 1000-1011
  CrossrefPubMedGoogle Scholar
• 20 Vizza CD, Hoeper MM, Huscher D. et al. Pulmonary hypertension in patients with COPD: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Chest 2021; 160 (02) 678-689
  CrossrefPubMedGoogle Scholar
• 21 Dauriat G, Reynaud-Gaubert M, Cottin V. et al; French group of investigators on severe PH-COPD. Severe pulmonary hypertension associated with COPD: long-term results of a prospective French multicentre cohort. Eur Respir J 2022; 60 (01) 2102897
  CrossrefPubMedGoogle Scholar
• 22 Boerrigter BG, Bogaard HJ, Trip P. et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 2012; 142 (05) 1166-1174
  CrossrefPubMedGoogle Scholar
• 23 Blanco I, Valeiro B, Torres-Castro R. et al. Effects of pulmonary hypertension on exercise capacity in patients with chronic obstructive pulmonary disease. Arch Bronconeumol (Engl Ed) 2020; 56 (08) 499-505
  CrossrefPubMedGoogle Scholar
• 24 Torres-Castro R, Gimeno-Santos E, Vilaró J. et al. Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis. Eur Respir Rev 2021; 30 (160) 200321
  CrossrefPubMedGoogle Scholar
• 25 Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]. 2022. Accessed June 20, 2023 at: https://goldcopd.org
  PubMed
• 26 Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32 (05) 1371-1385
  CrossrefPubMedGoogle Scholar
• 27 Thabut G, Dauriat G, Stern JB. et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127 (05) 1531-1536
  CrossrefPubMedGoogle Scholar
• 28 Kessler R, Faller M, Weitzenblum E. et al. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164 (02) 219-224
  CrossrefPubMedGoogle Scholar
• 29 Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130 (06) 993-998
  PubMedGoogle Scholar
• 30 Kovacs G, Avian A, Bachmaier G. et al. Severe pulmonary hypertension in copd: impact on survival and diagnostic approach. Chest 2022; 162 (01) 202-212
  CrossrefPubMedGoogle Scholar
• 31 Barberà JA, Riverola A, Roca J. et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 149 (2 Pt 1): 423-429
  CrossrefPubMedGoogle Scholar
• 32 Santos S, Peinado VI, Ramírez J. et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19 (04) 632-638
  CrossrefPubMedGoogle Scholar
• 33 Carlsen J, Hasseriis Andersen K, Boesgaard S, Iversen M, Steinbrüchel D, Bøgelund Andersen C. Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease. J Heart Lung Transplant 2013; 32 (03) 347-354
  CrossrefPubMedGoogle Scholar
• 34 Bunel V, Guyard A, Dauriat G. et al. Pulmonary arterial histologic lesions in patients with COPD with severe pulmonary hypertension. Chest 2019; 156 (01) 33-44
  CrossrefPubMedGoogle Scholar
• 35 Estépar RSJ, Kinney GL, Black-Shinn JL. et al; COPDGene Study. Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications. Am J Respir Crit Care Med 2013; 188 (02) 231-239
  CrossrefPubMedGoogle Scholar
• 36 Washko GR, Nardelli P, Ash SY. et al. Arterial vascular pruning, right ventricular size, and clinical outcomes in chronic obstructive pulmonary disease. A longitudinal observational study. Am J Respir Crit Care Med 2019; 200 (04) 454-461
  CrossrefPubMedGoogle Scholar
• 37 Dinh-Xuan AT, Higenbottam TW, Clelland CA. et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324 (22) 1539-1547
  CrossrefPubMedGoogle Scholar
• 38 Barberà JA, Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-Roisin R. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med 2001; 164 (04) 709-713
  CrossrefPubMedGoogle Scholar
• 39 Nana-Sinkam SP, Lee JD, Sotto-Santiago S. et al. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med 2007; 175 (07) 676-685
  CrossrefPubMedGoogle Scholar
• 40 Santos S, Peinado VI, Ramirez J. et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167 (09) 1250-1256
  CrossrefPubMedGoogle Scholar
• 41 Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131 (04) 493-498
  CrossrefPubMedGoogle Scholar
• 42 MacNee W, Wathen CG, Flenley DC, Muir AD. The effects of controlled oxygen therapy on ventricular function in patients with stable and decompensated cor pulmonale. Am Rev Respir Dis 1988; 137 (06) 1289-1295
  CrossrefPubMedGoogle Scholar
• 43 Vestbo J, Hurd SS, Agustí AG. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187 (04) 347-365
  CrossrefPubMedGoogle Scholar
• 44 Naeije R, Torbicki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 1995; 8 (09) 1445-1449
  CrossrefPubMedGoogle Scholar
• 45 Arcasoy SM, Christie JD, Ferrari VA. et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167 (05) 735-740
  CrossrefPubMedGoogle Scholar
• 46 Fisher MR, Criner GJ, Fishman AP. et al; NETT Research Group. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007; 30 (05) 914-921
  CrossrefPubMedGoogle Scholar
• 47 Seeger W, Adir Y, Barberà JA. et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62 (25, Suppl) D109-D116
  CrossrefPubMedGoogle Scholar
• 48 Blanco I, Santos S, Gea J. et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013; 42 (04) 982-992
  CrossrefPubMedGoogle Scholar
• 49 Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972; 286 (17) 912-918
  CrossrefPubMedGoogle Scholar
• 50 Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1 (8222): 681-686
  PubMedGoogle Scholar
• 51 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93 (03) 391-398
  CrossrefPubMedGoogle Scholar
• 52 Arif R, Pandey A, Zhao Y, Arsenault-Mehta K, Khoujah D, Mehta S. Treatment of pulmonary hypertension associated with COPD: a systematic review. ERJ Open Res 2022; 8 (01) 00348-02021
  CrossrefPubMedGoogle Scholar
• 53 Pandey A, Garg S, Khunger M. et al. Efficacy and safety of exercise training in chronic pulmonary hypertension: systematic review and meta-analysis. Circ Heart Fail 2015; 8 (06) 1032-1043
  CrossrefPubMedGoogle Scholar
• 54 Agustí AGN, Barberá JA, Roca J, Wagner PD, Guitart R, Rodriguez-Roisín R. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest 1990; 97 (02) 268-275
  CrossrefPubMedGoogle Scholar
• 55 Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med 1981; 304 (26) 1582-1585
  CrossrefPubMedGoogle Scholar
• 56 Roger N, Barberà JA, Roca J, Rovira I, Gómez FP, Rodriguez-Roisin R. Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156 (3 Pt 1): 800-806
  CrossrefPubMedGoogle Scholar
• 57 Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347 (8999): 436-440
  CrossrefPubMedGoogle Scholar
• 58 Vonbank K, Ziesche R, Higenbottam TW. et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003; 58 (04) 289-293
  CrossrefPubMedGoogle Scholar
• 59 Chen X, Tang S, Liu K. et al. Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension: a systematic review and meta-analysis. J Thorac Dis 2015; 7 (03) 309-319
  PubMedGoogle Scholar
• 60 Prins KW, Duval S, Markowitz J, Pritzker M, Thenappan T. Chronic use of PAH-specific therapy in World Health Organization group III pulmonary hypertension: a systematic review and meta-analysis. Pulm Circ 2017; 7 (01) 145-155
  CrossrefPubMedGoogle Scholar
• 61 Park J, Song JH, Park D-A, Lee JS, Lee S-D, Oh Y-M. Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease. J Korean Med Sci 2013; 28 (08) 1200-1206
  CrossrefPubMedGoogle Scholar
• 62 Vitulo P, Stanziola A, Confalonieri M. et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. J Heart Lung Transplant 2017; 36 (02) 166-174
  CrossrefPubMedGoogle Scholar
• 63 Travis WD, King TE, Bateman ED. et al; American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165 (02) 277-304
  PubMedGoogle Scholar
• 64 Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med 2020; 383 (10) 958-968
  CrossrefPubMedGoogle Scholar
• 65 Dhont S, Zwaenepoel B, Vandecasteele E, Brusselle G, De Pauw M. Pulmonary hypertension in interstitial lung disease: an area of unmet clinical need. ERJ Open Res 2022; 8 (04) 00272-02022
  CrossrefPubMedGoogle Scholar
• 66 King CS, Nathan SD. Pulmonary hypertension due to interstitial lung disease. Curr Opin Pulm Med 2019; 25 (05) 459-467
  CrossrefPubMedGoogle Scholar
• 67 Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015; 46 (04) 1113-1130
  CrossrefPubMedGoogle Scholar
• 68 Kimura M, Taniguchi H, Kondoh Y. et al. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 2013; 85 (06) 456-463
  CrossrefPubMedGoogle Scholar
• 69 Raghu G, Nathan SD, Behr J. et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J 2015; 46 (05) 1370-1377
  CrossrefPubMedGoogle Scholar
• 70 Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 2007; 82 (03) 342-350
  CrossrefPubMedGoogle Scholar
• 71 Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129 (03) 746-752
  CrossrefPubMedGoogle Scholar
• 72 King CS, Brown AW, Shlobin OA. et al. Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia. Eur Respir J 2018; 52 (01) 1800545
  CrossrefPubMedGoogle Scholar
• 73 Oliveira RKF, Pereira CAC, Ramos RP. et al. A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis. Eur Respir J 2014; 44 (02) 415-424
  CrossrefPubMedGoogle Scholar
• 74 Nadrous HF, Pellikka PA, Krowka MJ. et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128 (04) 2393-2399
  CrossrefPubMedGoogle Scholar
• 75 Martinez FJ, Safrin S, Weycker D. et al; IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142 (12 Pt 1): 963-967
  CrossrefPubMedGoogle Scholar
• 76 Piccari L, Wort SJ, Meloni F. et al; REHAR Registry Investigators. The effect of borderline pulmonary hypertension on survival in chronic lung disease. Respiration 2022; 101 (08) 717-727
  CrossrefPubMedGoogle Scholar
• 77 Ebina M, Shimizukawa M, Shibata N. et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169 (11) 1203-1208
  CrossrefPubMedGoogle Scholar
• 78 Weitzenblum E, Ehrhart M, Rasaholinjanahary J, Hirth C. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration 1983; 44 (02) 118-127
  CrossrefPubMedGoogle Scholar
• 79 Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341 (8860): 1550-1554
  CrossrefPubMedGoogle Scholar
• 80 Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004; 59 (07) 581-585
  CrossrefPubMedGoogle Scholar
• 81 Collum SD, Amione-Guerra J, Cruz-Solbes AS. et al. Pulmonary hypertension associated with idiopathic pulmonary fibrosis: current and future perspectives. Can Respir J 2017; 2017: 1430350
  CrossrefPubMedGoogle Scholar
• 82 Shiomi A, Usui T, Ishikawa Y, Shimizu M, Murakami K, Mimori T. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. J Immunol 2014; 193 (02) 849-859
  CrossrefPubMedGoogle Scholar
• 83 Agustí AGN, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez-Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991; 143 (02) 219-225
  CrossrefPubMedGoogle Scholar
• 84 Presberg KW, Dincer HE. Pathophysiology of pulmonary hypertension due to lung disease. Curr Opin Pulm Med 2003; 9 (02) 131-138
  CrossrefPubMedGoogle Scholar
• 85 Nathan SD, Shlobin OA, Ahmad S. et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76 (03) 288-294
  CrossrefPubMedGoogle Scholar
• 86 Nunes H, Humbert M, Capron F. et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61 (01) 68-74
  CrossrefPubMedGoogle Scholar
• 87 Lemmers JMJ, Vonk MC, van den Ende CHM. Patient-reported outcomes to assess dyspnoea in interstitial lung disease and pulmonary hypertension: a systematic literature review of measurement properties. Eur Respir Rev 2022; 31 (166) 220091
  CrossrefPubMedGoogle Scholar
• 88 Cottin V, Price LC, Valenzuela C. The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis. Eur Respir J 2018; 51 (01) 1702596
  CrossrefPubMedGoogle Scholar
• 89 Rahaghi FF, Kolaitis NA, Adegunsoye A. et al. Screening strategies for pulmonary hypertension in patients with interstitial lung disease: a multidisciplinary Delphi study. Chest 2022; 162 (01) 145-155
  CrossrefPubMedGoogle Scholar
• 90 Bonay M, Bancal C, de Zuttere D, Arnoult F, Saumon G, Camus F. Normal pulmonary capillary blood volume in patients with chronic infiltrative lung disease and high pulmonary artery pressure. Chest 2004; 126 (05) 1460-1466
  CrossrefPubMedGoogle Scholar
• 91 Nathan SD, Shlobin OA, Barnett SD. et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008; 102 (09) 1305-1310
  CrossrefPubMedGoogle Scholar
• 92 Aliberti S, Messinesi G, Gamberini S. et al. Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases. BMC Pulm Med 2014; 14: 194
  CrossrefPubMedGoogle Scholar
• 93 Kennedy JI, Fulmer JD. Pulmonary hypertension in the interstitial lung diseases. Chest 1985; 87 (05) 558-560
  CrossrefPubMedGoogle Scholar
• 94 Ghofrani HA, Wiedemann R, Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360 (9337): 895-900
  CrossrefPubMedGoogle Scholar
• 95 Olschewski H, Ghofrani HA, Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160 (02) 600-607
  CrossrefPubMedGoogle Scholar
• 96 Blanco I, Ribas J, Xaubet A. et al. Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis. J Appl Physiol 2011; 110 (03) 638-645
  CrossrefPubMedGoogle Scholar
• 97 Rochwerg B, Neupane B, Zhang Y. et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med 2016; 14: 18
  CrossrefPubMedGoogle Scholar
• 98 Nathan SD, Behr J, Collard HR. et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019; 7 (09) 780-790
  CrossrefPubMedGoogle Scholar
• 99 Zhao N, Chen J, Zhang M. et al. PAH-specific therapy for pulmonary hypertension and interstitial lung disease: a systemic review and meta-analysis. Front Cardiovasc Med 2022; 9: 992879
  CrossrefPubMedGoogle Scholar
• 100 Waxman A, Restrepo-Jaramillo R, Thenappan T. et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 2021; 384 (04) 325-334
  CrossrefPubMedGoogle Scholar
• 101 Nathan SD, Waxman A, Rajagopal S. et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med 2021; 9 (11) 1266-1274
  CrossrefPubMedGoogle Scholar
• 102 Clapp LH, Gurung R. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat 2015; 120: 56-71
  CrossrefPubMedGoogle Scholar
• 103 Mitchell JA, Ahmetaj-Shala B, Kirkby NS. et al. Role of prostacyclin in pulmonary hypertension. Glob Cardiol Sci Pract 2014; 2014 (04) 382-393
  PubMedGoogle Scholar
• 104 Kolb M, Orfanos SE, Lambers C. et al. The antifibrotic effects of inhaled treprostinil: an emerging option for ILD. Adv Ther 2022; 39 (09) 3881-3895
  CrossrefPubMedGoogle Scholar
• 105 Nathan SD, Tapson VF, Elwing J. et al. Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE Trial. Am J Respir Crit Care Med 2022; 205 (02) 198-207
  CrossrefPubMedGoogle Scholar
• 106 Nathan S, Argula R, Rajagopal S. et al. Inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease: event-free survival in INCREASE study open-label extension. Eur Respir J 2022; 60 (suppl 66): 2133
  PubMedGoogle Scholar
• 107 Cottin V, Selman M, Inoue Y. et al. Syndrome of combined pulmonary fibrosis and emphysema: an official ATS/ERS/JRS/ALAT research statement. Am J Respir Crit Care Med 2022; 206 (04) e7-e41
  CrossrefPubMedGoogle Scholar
• 108 Schiess R, Senn O, Fischler M. et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest 2010; 138 (05) 1086-1092
  CrossrefPubMedGoogle Scholar
• 109 Cottin V, Le Pavec J, Prévot G. et al; GERM“O”P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35 (01) 105-111
  CrossrefPubMedGoogle Scholar
• 110 Nathan SD, Cottin V. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Eur Respir Monogr 2012; 57: 148-160
  PubMedGoogle Scholar
• 111 Awano N, Inomata M, Ikushima S. et al. Histological analysis of vasculopathy associated with pulmonary hypertension in combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis or emphysema alone. Histopathology 2017; 70 (06) 896-905
  CrossrefPubMedGoogle Scholar
• 112 Mejía M, Carrillo G, Rojas-Serrano J. et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136 (01) 10-15
  CrossrefPubMedGoogle Scholar
• 113 Jacob J, Bartholmai BJ, Rajagopalan S. et al. Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema. Respirology 2018; 23 (06) 593-599
  CrossrefPubMedGoogle Scholar
• 114 Jacob J, Bartholmai BJ, Rajagopalan S. et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J 2017; 50 (01) 1700379
  CrossrefPubMedGoogle Scholar
• 115 Cottin V, Nunes H, Brillet PY. et al; Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26 (04) 586-593
  CrossrefPubMedGoogle Scholar
• 116 Ferrer E, Peinado VI, Castañeda J. et al. Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig. Eur Respir J 2011; 38 (03) 617-627
  CrossrefPubMedGoogle Scholar
• 117 Hoeper MM, Behr J, Held M. et al. Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias. PLoS One 2015; 10 (12) e0141911
  CrossrefPubMedGoogle Scholar
• 118 Zimmermann GS, von Wulffen W, Huppmann P. et al. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology 2014; 19 (05) 700-706
  CrossrefPubMedGoogle Scholar
• 119 Nathan SD, Cottin V, Behr J. et al. Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. J Heart Lung Transplant 2021; 40 (06) 494-503
  CrossrefPubMedGoogle Scholar
• 120 Boucly A, Cottin V, Nunes H. et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50 (04) 1700465
  CrossrefPubMedGoogle Scholar
• 121 Gupta R, Zheng M, Gangemi AJ. et al. Predictors of lung transplant waitlist mortality for sarcoidosis. Respir Med 2022; 205: 107008
  CrossrefPubMedGoogle Scholar
• 122 Sharma B, Owens R, Malhotra A. Sleep in congestive heart failure. Med Clin North Am 2010; 94 (03) 447-464
  CrossrefPubMedGoogle Scholar
• 123 Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest 2013; 144 (01) 169-176
  CrossrefPubMedGoogle Scholar
• 124 Thurnheer R, Ulrich S, Bloch KE. Precapillary pulmonary hypertension and sleep-disordered breathing: is there a link?. Respiration 2017; 93 (01) 65-77
  CrossrefPubMedGoogle Scholar
• 125 Kholdani C, Fares WH, Mohsenin V. Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology. Pulm Circ 2015; 5 (02) 220-227
  CrossrefPubMedGoogle Scholar
• 126 Held M, Walthelm J, Baron S, Roth C, Jany B. Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation. Eur Respir J 2014; 43 (01) 156-165
  CrossrefPubMedGoogle Scholar
• 127 Sugerman HJ, Baron PL, Fairman RP, Evans CR, Vetrovec GW. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 1988; 207 (05) 604-613
  CrossrefPubMedGoogle Scholar
• 128 Sharma S, Stansbury R, Hackett B, Fox H. Sleep apnea and pulmonary hypertension: a riddle waiting to be solved. Pharmacol Ther 2021; 227: 107935
  CrossrefPubMedGoogle Scholar
• 129 Ulrich S, Keusch S, Hildenbrand FF. et al. Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial. Eur Heart J 2015; 36 (10) 615-623
  CrossrefPubMedGoogle Scholar